As the year comes to a close, we are reflecting on both our accomplishments, and the opportunities ahead of us in 2025! Thank you to our talented team and dedicated partners for your continued commitment and support. Here’s to a great year ahead!
About us
Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or follow us at @agenus_bio. Our Community Guidelines are available at our website and at: https://agenusbio.com/community-guidelines/
- Website
-
https://agenusbio.com/.
External link for Agenus
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Lexington, Massachusetts
- Type
- Public Company
- Founded
- 1994
- Specialties
- Immuno-oncology, Cancer Vaccines, Checkpoint Inhibitors and Modulators, Immunotherapy, Cell therapy, Antibodies, and GMP Manufacturing
Locations
-
Primary
Get directions
3 Forbes Road
Lexington, Massachusetts 02421, US
Employees at Agenus
-
Brian Greenblatt
-
Doreene Burke
Head of Global Supply Chain at Agenus
-
Tracy Clemente
Chief Human Resources Officer @ Agenus
-
Bob Durham, Designing Destination Health Intel
We promote Medical Travel Revenues with Top-Level Destinations by taking advantage of Destination Health Intelligence!
Updates
-
For 30 years, we have been at the forefront of immuno-oncology. We’re proud of our cutting-edge manufacturing facilities, including our newest facility in California, designed to accelerate the commercialization of innovative therapies. Equipped with cutting-edge technology and a fully integrated CGMP unit for biologics development and manufacturing, this state-of-the-art space enhances our ability to produce therapies more efficiently and at greater scale—ensuring faster access for patients in need. Read more about our commitment to innovation and research: https://lnkd.in/epHkwneU
-
-
We’re excited to announce five presentations at the 2025 American Society of Clinical Oncology (ASCO) GI Symposium next month in San Francisco. The presentations will highlight new data on BOT/BAL’s potential across lines of treatment in #ColorectalCancer, including the neoadjuvant setting. As CEO Dr. Garo Armen shares, “We aim to transform outcomes at every stage of disease and deliver renewed hope for patients worldwide.” Learn more: https://bit.ly/3PnAVOR #ASCO25
-
-
We were honored to participate in the inaugural Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer, hosted by OncoDaily. Our VP of Research, Dhan Chand, joined global leaders to share insights and explore innovative approaches to improving #ColorectalCancer care. Collaboration is key to advancing solutions, and we’re proud to contribute to this critical dialogue. Watch now: https://bit.ly/4ftNyT6
-
-
Agenus is proud to announce a collaboration with Tanner Pharma Group to provide expanded access to our investigational immunotherapies through a Named Patient Program. This program addresses urgent needs for eligible patients with microsatellite stable #ColorectalCancer (MSS CRC) and other advanced solid tumors by enabling access to our investigational treatments in regions where named patient access is permitted.
Tanner Pharma is thrilled to announce our partnership with Agenus to expand access to botensilimab (BOT) and balstilimab (BAL) through a Named Patient Program (NPP). This initiative aims to provide patients with microsatellite stable colorectal cancer (MSS CRC) and other advanced solid tumors the opportunity to access these investigational immunotherapies. BOT and BAL have shown promising clinical outcomes, including complete pathological responses and durable tumor responses across multiple cancer types. This partnership underscores our commitment to supporting patients and healthcare providers by offering new hope for improved survival and quality of life. https://lnkd.in/gJ-AxHzs #TannerPharma #Agenus #NamedPatientProgram #CancerTreatment #HealthcareInnovation
-
-
Agenus is proud to be a sponsor of Fight Colorectal Cancer’s 2024 Colorectal Cancer Care Report and to support the CRCCI in addressing critical gaps in #ColorectalCancer care. Download the report here: https://bit.ly/4970lJw
We've brought together a diverse group of partners to launch the Colorectal Cancer Care Initiative (CRCCI)—a powerful coalition dedicated to tackling some of the most pressing challenges in colorectal cancer care through shared expertise and resources. 💪💙 Check out the CRCCI, and see how you can be involved: https://lnkd.in/eJwmYAbH Thank you to everyone who shared their insights and expertise to help shape the Colorectal Cancer Care Report! And a special shoutout to the dedicated working group members for their contributions. Primary Contributors and Reviewers: Anjee Q. Davis, Fight CRC Andrea Dwyer, University of Colorado Cancer Center, Fight CRC Cathy Eng, Vanderbilt University Richard Goldberg, West Virginia University Cancer Institute Samir Gupta, UC San Diego Rachel Issaka, MD, MAS, Fred Hutch David Lieberman, Oregon Health & Science University Folasade (Fola) May, MD, PhD, UCLA Health Molly McDonnell, Fight CRC Rebecca Siegel, American Cancer Society Ben White, MPP, Fight CRC Ann Zauber, Memorial Sloan Kettering Cancer Center Data Contributors: Freenome, Komodo Health, Epic, Flatiron Health Case Study Contributors: Exact Sciences, Inspira Health, American Society for Gastrointestinal Endoscopy (ASGE), Kaiser Permanente
-
-
Today is World Pancreatic Cancer Day and Agenus is proud to join Pancreatic Cancer Action Network in raising awareness of #PancreaticCancer. Early detection is critical to increasing survival, but currently there is no standard test to find pancreatic cancer early. Learn more about the steps everyone can take to be proactive about their health: pancan.org/awareness #PanCANawareness
-
-
Today we announced our third-quarter financial results and shared a corporate update. Discover the latest progress and insights from this quarter here: https://bit.ly/40Modjl
-
-
At #SITC24 we are presenting new data from our investigational immunotherapy programs, including botensilimab and AGEN1721. Explore our latest advancements in cancer research here: https://bit.ly/3ClYdBq
-
-
This past weekend, Agenus was proud to support Colorectal Cancer Alliance’s National Blue Hope Bash, a gathering of passionate allies committed to raising awareness and support for #colorectalcancer research and advocacy.
-